Devin Sok

List of Publications by Year in Descending Order

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78 papers	7,935 citations	43 h-index	89 g-index
89 ext. papers	9,917 ext. citations	18 avg, IF	5.64 L-index

#	Paper	IF	Citations
78	From structure to sequence: Antibody discovery using cryoEM.. *Science Advances*, **2022**, 8, eabk2039	14.3	2
77	Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer.. *Cell Reports*, **2022**, 38, 110485	10.6	0
76	A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant.. *PLoS Pathogens*, **2022**, 18, e1010465	7.6	1
75	Rapid cGMP manufacturing of COVID-19 monoclonal antibody using stable CHO cell pools. *Biotechnology and Bioengineering*, **2021**, 119, 663	4.9	0
74	Elicitation of potent serum neutralizing antibody responses in rabbits by immunization with an HIV-1 clade C trimeric Env derived from an Indian elite neutralizer. *PLoS Pathogens*, **2021**, 17, e1008977	7.6	0
73	Nature or nurture: Factors that influence bnAb development. *Cell Host and Microbe*, **2021**, 29, 540-542	23.4	1
72	Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities. *Retrovirology*, **2021**, 18, 12	3.6	
71	Structural basis of broad HIV neutralization by a vaccine-induced cow antibody. *Science Advances*, **2020**, 6, eaba0468	14.3	14
70	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science*, **2020**, 369, 956-963	33.3	906
69	Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit Vaccines. *Cell Reports*, **2020**, 30, 3755-3765.e7	10.6	49
68	Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model **2020**,		35
67	Structural basis of a public antibody response to SARS-CoV-2 **2020**,		14
66	Mapping Neutralizing Antibody Epitope Specificities to an HIV Env Trimer in Immunized and in Infected Rhesus Macaques. *Cell Reports*, **2020**, 32, 108122	10.6	12
65	Structural basis of a shared antibody response to SARS-CoV-2. *Science*, **2020**, 369, 1119-1123	33.3	338
64	Systems Biology Methods Applied to Blood and Tissue for a Comprehensive Analysis of Immune Response to Hepatitis B Vaccine in Adults. *Frontiers in Immunology*, **2020**, 11, 580373	8.4	8
63	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. *PLoS Pathogens*, **2020**, 16, e1008753	7.6	37
62	A V1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite. *Science Advances*, **2020**, 6,	14.3	4

61	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates **2020**, 16, e1008753		
60	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates **2020**, 16, e1008753		
59	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates **2020**, 16, e1008753		
58	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates **2020**, 16, e1008753		
57	Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles. *Molecular Therapy*, **2019**, 27, 2080-2090	11.7	27
56	Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan. *Immunity*, **2019**, 51, 141-154.e6	32.3	38
55	A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. *Science*, **2019**, 366,	33.3	89
54	Reprogramming the antigen specificity of B cells using genome-editing technologies. *ELife*, **2019**, 8,	8.9	30
53	Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry. *Journal of Virology*, **2018**, 92,	6.6	21
52	Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. *JCI Insight*, **2018**, 3,	9.9	12
51	HIV-1 vaccine design through minimizing envelope metastability. *Science Advances*, **2018**, 4, eaau6769	14.3	43
50	Recent progress in broadly neutralizing antibodies to HIV. *Nature Immunology*, **2018**, 19, 1179-1188	19.1	186
49	Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer. *Nature Communications*, **2018**, 9, 3693	17.4	87
48	Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. *Science Translational Medicine*, **2017**, 9,	17.5	96
47	Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers. *MBio*, **2017**, 8,	7.8	22
46	Immunochemical engineering of cell surfaces to generate virus resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 4655-4660	11.5	4
45	A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic □Hairpin Structure. *Immunity*, **2017**, 46, 690-702	32.3	146
44	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. *Immunity*, **2017**, 46, 1073-1088.e6	32.3	204

43	Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. *Nature Communications*, **2017**, 8, 14954	17.4	133
42	Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. *Science Translational Medicine*, **2017**, 9,	17.5	69
41	Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. *Cell Reports*, **2017**, 21, 222-235	10.6	40
40	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. *Science Translational Medicine*, **2017**, 9,	17.5	65
39	Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. *Nature*, **2017**, 548, 108-111	50.4	99
38	Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. *Science Immunology*, **2017**, 2,	28	68
37	Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer. *Frontiers in Immunology*, **2017**, 8, 1025	8.4	14
36	Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. *PLoS Pathogens*, **2017**, 13, e1006212	7.6	42
35	Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. *Cell Reports*, **2016**, 16, 2327-38	10.6	163
34	Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. *Science*, **2016**, 353, 1045-1049	33.3	107
33	Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. *Cell Reports*, **2016**, 17, 2195-2209	10.6	110
32	A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. *Immunity*, **2016**, 45, 31-45	32.3	97
31	HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98. *Immunity*, **2016**, 45, 958-960	32.3	7
30	HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. *Science*, **2016**, 351, 1458-63	33.3	266
29	Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. *Science* , **2016**, 351, 1078-83	33.3	153
28	An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. *Nature Microbiology*, **2016**, 2, 16199	26.6	103
27	Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. *PLoS Pathogens*, **2016**, 12, e1005815	7.6	76
26	Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. *Nature Communications*, **2016**, 7, 12040	17.4	86

25	Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. *Nature Communications*, **2016**, 7, 12041	17.4	101
24	Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. *Science*, **2016**, 353, 1557-1560	33.3	106
23	Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. *Cell*, **2016**, 166, 1459-1470.e11	56.2	178
22	Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. *Cell*, **2016**, 166, 1445-1458.e12	56.2	204
21	HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. *Science*, **2015**, 349, 156-61	33.3	264
20	HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. *Science*, **2015**, 349, aac4223	33.3	394
19	Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. *Journal of Virology*, **2015**, 89, 10383-98	6.6	105
18	Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. *Virology*, **2015**, 475, 37-45	3.6	21
17	Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. *Journal of Virology*, **2015**, 89, 1105-18	6.6	67
16	Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. *PLoS Pathogens*, **2015**, 11, e1005110	7.6	61
15	Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding. *Scientific Reports*, **2014**, 4, 6778	4.9	70
14	Structural evolution of glycan recognition by a family of potent HIV antibodies. *Cell*, **2014**, 159, 69-79	56.2	147
13	Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. *Science Translational Medicine*, **2014**, 6, 236ra63	17.5	148
12	Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 17624-9	11.5	239
11	Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy. *Journal of Virology*, **2014**, 88, 10177-88	6.6	53
10	Crystal structure of a soluble cleaved HIV-1 envelope trimer. *Science*, **2013**, 342, 1477-83	33.3	687
9	Rational HIV immunogen design to target specific germline B cell receptors. *Science*, **2013**, 340, 711-6	33.3	519
8	The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. *PLoS Pathogens*, **2013**, 9, e1003754	7.6	144

7	Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. *PLoS Pathogens*, **2013**, 9, e1003342	7.6	235
6	Anti-HIV B Cell lines as candidate vaccine biosensors. *Journal of Immunology*, **2012**, 189, 4816-24	5.3	48
5	Mapping Neutralizing Antibody Epitope Specificities to an HIV Env Trimer in Immunized and in Infected Rhesus Macaques. *SSRN Electronic Journal*,	1	1
4	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates		7
3	Mapping polyclonal antibody responses in non-human primates vaccinated with HIV Env trimer subunit vaccines		5
2	From Structure to Sequence: Identification of polyclonal antibody families using cryoEM		1
1	Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution		3